Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) EBT (2019 - 2025)

Historic EBT for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$112.7 million.

  • Beam Therapeutics' EBT fell 1661.36% to -$112.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$414.8 million, marking a year-over-year decrease of 20544.55%. This contributed to the annual value of -$376.7 million for FY2024, which is 18720.66% down from last year.
  • As of Q3 2025, Beam Therapeutics' EBT stood at -$112.7 million, which was down 1661.36% from -$102.3 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' EBT registered a high of $144.2 million during Q4 2023, and its lowest value of -$200.4 million during Q1 2021.
  • In the last 5 years, Beam Therapeutics' EBT had a median value of -$89.0 million in 2023 and averaged -$76.1 million.
  • As far as peak fluctuations go, Beam Therapeutics' EBT crashed by 62193.24% in 2021, and later surged by 48598.89% in 2023.
  • Over the past 5 years, Beam Therapeutics' EBT (Quarter) stood at -$64.7 million in 2021, then surged by 42.28% to -$37.3 million in 2022, then surged by 485.99% to $144.2 million in 2023, then crashed by 162.67% to -$90.4 million in 2024, then fell by 24.76% to -$112.7 million in 2025.
  • Its last three reported values are -$112.7 million in Q3 2025, -$102.3 million for Q2 2025, and -$109.4 million during Q1 2025.